MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
7.84
0.00
0.00%
After Hours: 7.92 +0.08 +1.02% 19:48 02/11 EST
OPEN
7.80
PREV CLOSE
7.84
HIGH
7.87
LOW
7.50
VOLUME
859.36K
TURNOVER
--
52 WEEK HIGH
12.49
52 WEEK LOW
5.41
MARKET CAP
682.22M
P/E (TTM)
-3.1638
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KURA last week (0202-0206)?
Weekly Report · 2d ago
Kura Oncology reports inducement grants under Nasdaq listing rule
TipRanks · 5d ago
Kura Oncology vergibt Aktienoptionen an neue Mitarbeiter
Reuters · 5d ago
Kura Oncology Grants Stock Options to New Employees Under Inducement Plan
Reuters · 5d ago
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026
Simply Wall St · 5d ago
Barclays Remains a Buy on Kura Oncology (KURA)
TipRanks · 02/04 09:18
Bank of America Securities Remains a Buy on Kura Oncology (KURA)
TipRanks · 02/03 12:09
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.